Novo Nordisk (NYSE:NVO) said today that the European Union’s Committee for Medicinal Products for Human Use issued a positive opinion on its fast-acting insulin analogue, Fiasp. The Danish company also committed to expanding its Changing Diabetes in Children program, which provides access to diabetes care and free insulin to children with Type I diabetes in developing countries.
The committee, under the European Medicines Agency, recommended marketing authorization for adults withType I and Type II diabetes. Fiasp is a fast-acting mealtime insulin that has a greater glucose-lowering effect than Nordisk’s NovoRapid insulin. The committee recommended that the European Commission indicate Fiasp for use as the bolus component of basal-bolus therapy in combination with basal insulin and for insulin infusion using an insulin pump.